Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

The candidate is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster Dupixent in allergy ...

French drugmaker adds Ayvakit and next-gen immunology pipeline in strategic move to dominate rare disease space Sanofi has ...

Walt Disney is laying off several hundred people globally across multiple divisions, including marketing for film and television, TV publicity, casting and development, and corporate financial ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Kymera Therapeutics reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent ...